Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How the Mayo Clinic Board Balances Medicine and Business
Transcript
- Lucas: When we think about boards that actually work, we usually talk about for-profit giants — Apple, Costco, Berkshire. But there's a nonprofit organization that runs like a Fortune 500 company, generates over sixteen billion dollars a year, and has a board structure that's been refined over more than a century. I'm talking about the Mayo Clinic. Luna: Mayo's fascinating because it's not a hospital chain in the traditional sense. It's a physician-led, nonprofit academic medical center. And it's consistently ranked number one in more specialties than any other hospital. Lucas: Exactly. And the board is central to how they maintain that. Mayo has what they call a 'three-shield model' — patient care, research, and education. The board's job is to balance all three, even when financial pressures might push them to prioritize just one. Luna: So how is the board structured? Is it like a typical corporate board with independent directors? Lucas: It's a board of trustees, and it's a mix. As of 2026, there are sixteen trustees. About half are physicians — many from within Mayo — but the rest are external leaders from business, academia, and other fields. For example, there's a former CEO of Medtronic, a former dean of Harvard Medical School, and a former U.S. Surgeon General. The idea is you get clinical credibility AND outside perspective. Luna: That physician-led piece is crucial. Because if you look at what went wrong at for-profit hospital chains like HCA or Tenet, a lot of it stemmed from boards that prioritized revenue over quality. Mayo's board seems wired differently. Lucas: Right. And the financial results still speak for themselves. Mayo generates about sixteen and a half billion dollars in annual revenue — that's larger than many Fortune 500 companies. They have an operating margin that hovers around three to four percent, which for a nonprofit is actually quite healthy. They reinvest virtually everything back into the mission. Luna: But let's talk about a concrete strategic decision. Mayo expanded aggressively into Arizona and Florida over the past two decades. How did the board handle that? Lucas: That's a great case. The expansion into Scottsdale started in the 1980s, and then Jacksonville in the 1990s. But the big push came in the 2010s. The board had to approve hundreds of millions in capital expenditures — new buildings, new equipment, recruiting top physicians. The key was that they didn't just replicate Rochester; they adapted the model to each market. In Florida, for instance, they built a cancer center that partners with local insurers differently. Luna: And the board had to weigh the risk of diluting the Mayo brand. If you open a campus that doesn't deliver the same quality, you hurt the entire institution. Lucas: Exactly. So the board insisted on what they call a 'one Mayo' approach — same governance, same quality standards, same electronic health records system. They didn't franchise. They expanded the partnership model. Luna: Speaking of electronic health records, Mayo invested heavily in data and analytics. They launched something called the Mayo Clinic Platform, which aggregates de-identified patient data for research. That's a big bet on data monetization. Lucas: And the board had to navigate serious privacy and ethical considerations. They're essentially creating a data asset that has commercial value, but they're a nonprofit. The board's solution was to set up a separate entity called Mayo Clinic Ventures to handle commercialization, with strict governance firewalls. Any revenue goes back into the mission. Luna: That sounds like a model other academic medical centers could copy. But let's shift to a different challenge — the COVID-19 pandemic. How did the board respond? Lucas: Mayo was actually one of the first health systems to roll out widespread testing in early 2020. The board approved a massive shift in resources — they converted operating rooms into ICU beds, redeployed staff, and launched a telehealth platform virtually overnight. They spent about a billion dollars on that infrastructure. The board met weekly during the peak. Luna: And they had to make decisions about which patients to prioritize, how to allocate PPE, how to handle the financial hit from canceled elective procedures. Nonprofit boards don't always get credit for crisis management, but this was a real test. Lucas: Before we go deeper, I want to mention something that makes these conversations possible. We keep this show ad-free and accessible to everyone, and that's because of listeners who chip in a few dollars a month at buy me a coffee dot com slash fexingo. If these episodes have helped you think differently about how organizations are run, that's the place to support the work. Luna: Yeah, it genuinely makes a difference. Even small contributions add up and let us keep digging into stories like this one. Lucas: Right. So back to Mayo. One of the most interesting governance questions is how the board handles the tension between local autonomy and system-wide alignment. Each campus has its own administrative leadership, but the board oversees the whole system. They use a committee structure that mirrors the three shields — patient care, research, education — plus finance and audit. Luna: And they have a community benefit committee too, right? Because as a nonprofit, they have to demonstrate that they're serving the public. Lucas: Yes. Mayo publishes an annual community benefit report. In 2025, they reported about one point three billion dollars in community benefit — that includes uncompensated care, research funding, and education. The board reviews that report and sets targets. It's not just a compliance exercise; it's part of their strategic planning. Luna: But here's a question: nonprofit boards are often criticized for being less accountable than for-profit boards. There's no shareholder vote, no activist investor pushing for change. How does Mayo's board stay sharp? Lucas: That's a fair critique. Mayo addresses it through a few mechanisms. First, the board conducts regular self-assessments, including peer reviews. Second, they have term limits — trustees serve staggered six-year terms, renewable once. And third, they tie executive compensation to quality metrics, not just financial performance. The CEO's bonus, for example, depends on patient satisfaction scores, clinical outcomes, and research output. Luna: So the board itself is held to a standard of continuous improvement. Have there been any notable governance failures or controversies? Lucas: Not major scandals, but there have been debates. In 2023, there was a dispute over whether Mayo should invest in a for-profit health insurance venture. Some trustees argued it would blur the nonprofit mission. The board ultimately approved a limited pilot, but with strict oversight and a sunset clause. That kind of debate is healthy — it shows the board is wrestling with real trade-offs. Luna: I want to talk about the board's role in succession planning. Who's on the current board, and how do they think about the next generation of leadership? Lucas: The current chair is a former CEO of a major health insurance company, and the vice chair is a physician from within Mayo. The board explicitly looks for diversity of thought — they have clinicians, academics, former government officials, and business leaders. They also have a formal succession plan for the CEO and the board itself. They identify potential future trustees years in advance and give them exposure to the board's work. Luna: So it's not just about filling seats when someone retires. It's about building a pipeline. Lucas: Exactly. And that's something many for-profit boards could learn from. Too often, corporate boards recruit people who look and think like the existing members. Mayo's board actively seeks out people who will challenge assumptions — including, notably, patients. They have a patient advisory council that reports to the board annually. Luna: That's unusual. Most hospital boards have patient representatives, but they're often token. Mayo seems to take it seriously. Lucas: They do. The patient council has helped shape everything from appointment scheduling to the design of new facilities. The board pays attention because they know patient experience directly affects their reputation and, ultimately, their revenue. Luna: Let's talk about the financial side a bit more. Mayo has an endowment of about fifteen billion dollars. How does the board oversee that? Lucas: They have an investment committee that includes trustees with finance backgrounds — people who have run hedge funds or served on the investment committees of major universities. The endowment is managed with a long-term horizon, targeting a mix of equities, fixed income, and alternative assets. The board's policy is to spend about five percent annually, which is standard for endowments. Luna: But unlike a university endowment, Mayo's endowment has to support a clinical enterprise. If the market drops, they can't just cut spending on patient care. Lucas: Right. That's why the board uses a smoothing rule — they don't adjust spending based on annual market fluctuations. They use a three-year rolling average of the endowment's value. That gives the operating budget more stability. Luna: So the governance structure is designed to be resilient. I'm curious — are there any lessons here for non-healthcare boards? Lucas: I think so. First, the idea of having a clear, mission-driven 'primary value' that every decision is tested against. Mayo's primary value is 'the needs of the patient come first.' That sounds simple, but it forces trade-offs. Second, the board's willingness to invest in long-term capabilities — like data infrastructure and physician training — even when it depresses short-term margins. Third, the commitment to physician leadership at the board level. That's rare in any industry. Luna: And the humility to learn from outside perspectives. Mayo's board includes people from completely different sectors — like a former CEO of a manufacturing company. That cross-pollination is valuable. Lucas: Absolutely. The manufacturing CEO brings a perspective on operational efficiency and supply chain management that a physician might not have. And the physician brings clinical insight that the business person lacks. The boardroom becomes a place where those worldviews collide constructively. Luna: So what's the biggest challenge facing the Mayo board right now? Lucas: I'd say it's the shift to value-based care. Medicare and private insurers are increasingly paying based on outcomes, not procedures. That's actually good for Mayo's model — they've always focused on quality — but it requires transforming how they operate. The board is overseeing a multi-year initiative to redesign care pathways, invest in population health analytics, and partner with employers directly. It's a bet that will take a decade to pay off. Luna: And the board has to stay disciplined about not chasing revenue growth at the expense of mission. That's the perennial tension. Lucas: Right. But if any board has proven it can manage that tension, it's Mayo's. They've been doing it for over a hundred years. Luna: And they've set a standard that other healthcare organizations — and maybe even non-healthcare organizations — could aspire to. Lucas: That's the takeaway. A great board is not about having famous names on the letterhead. It's about having the right composition, the right processes, and the discipline to stay true to your mission even when it's hard. Luna: Well said.